Coloplast A/S - Announcement no. 07/2023 – Coloplast announces completion of offering of 12.2 million new B shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

Coloplast announces completion of offering of 12.2 million new B shares in a directed issue and private placement

On 29 August 2023, Coloplast A/S (“Coloplast") announced its intention to raise new capital through an accelerated book-building process. The offering (the "Offering") of new B shares (the “New Shares”) in Coloplast has now been successfully completed. Reference is made to company announcement no. 6/2023 of 29 August 2023.

Coloplast has successfully completed a directed issue and private placement of 12.2 million New Shares at an offer price of DKK 755 per New Share, raising gross proceeds to Coloplast of approximately DKK 9.2 billion.

The Offering was made pursuant to applicable exemptions from the obligation to publish a prospectus in a directed issue and private placement and subscribed for by qualified institutional and other professional investors in Denmark and in certain other jurisdictions as well as certain other persons as announced in company announcement no. 6/2023 of 29 August 2023 at market price and without pre-emption rights for Coloplast's existing shareholders.

The net proceeds from the Offering will be used in accordance with company announcement no. 6/2023 of 29 August 2023.

As the Offering was oversubscribed, an individualized allocation of the New Shares was made.

Coloplast has in connection with the Offering agreed to undertake a lock-up commitment for 180 calendar days following settlement of the Offering (subject to certain exceptions). In addition, members of Coloplast's Board of Directors as well as members of the Executive Management have in connection with the Offering agreed to undertake a lock-up commitment for 180 calendar days following settlement of the Offering (subject to certain exceptions).

Capital increase

Subject to settlement, a share capital increase will be registered with the Danish Business Authority and the share capital of Coloplast will hereafter amount to nominally DKK 228.2 million, of which DKK 18 million is A shares divided into shares of DKK 1.00 each or multiples thereof, and DKK 210.2 million is B shares divided into shares of DKK 1 each.